Molecular Cloning and Characterization of p56 dok-2 Defines a New Family of RasGAP-binding Proteins*

Chronic myelogenous leukemia (CML) is a disease characterized by the presence of p210 bcr-abl , a chimeric protein with tyrosine kinase activity. Substrates for p210 bcr-abl are likely to be involved in the pathogenesis of CML. Here we describe the purification, cDNA cloning, and characterization of a 56-kDa tyrosine phosphorylated protein, p56 dok-2 (Dok-2), from p210 bcr-abl expressing cells. The human dok-2 cDNA encodes a 412-amino acid protein with a predicted N-terminal pleckstrin homology domain as well as several other features of a signaling molecule, including 13 potential tyrosine phosphorylation sites, six PXXP motifs, and the ability to bind to p120 RasGAP . Dok-2 was shown to be 35% identical to p62 dok-1 , a recently identified RasGAP binding protein from CML cells, and analysis of the expressed sequence tag data base revealed the presence of at least four additional proteins containing a Dok homology sequence motif. Dok mRNAs were primarily expressed in tissues of hematopoietic origin. These findings strongly suggest that a family of Dok-related proteins exists that bind to RasGAP and may mediate the effects of p210 bcr-abl in CML.

[1]  J. Settleman,et al.  Tandem SH2 binding sites mediate the RasGAP–RhoGAP interaction: a conformational mechanism for SH3 domain regulation , 1997, The EMBO journal.

[2]  D. Baltimore,et al.  Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok , 1997, Cell.

[3]  R. Kobayashi,et al.  p62 dok : A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells , 1997, Cell.

[4]  J. Bishop,et al.  Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Sawyers,et al.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene , 1995, The Journal of experimental medicine.

[6]  M. Resh,et al.  Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. , 1994, The Journal of biological chemistry.

[7]  B. Clarkson,et al.  A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations. , 1994, Leukemia.

[8]  T Pawson,et al.  Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.

[9]  A. Strife,et al.  Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. , 1993, Leukemia.

[10]  J. Wang,et al.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins , 1991, Molecular and cellular biology.

[11]  M. Weber,et al.  Comparison of three methods for detecting tyrosine-phosphorylated proteins. , 1991, Methods in enzymology.

[12]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[13]  G. Cattoretti,et al.  Selective growth response to IL‐3 of a human leukaemic cell line with megakaryoblastic features , 1988, British journal of haematology.

[14]  J. Gordon,et al.  The biology and enzymology of eukaryotic protein acylation. , 1988, Annual review of biochemistry.

[15]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[16]  J. Garrels [28] Quantitative two-dimensional gel electrophoresis of proteins , 1983 .

[17]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[18]  P. O’Farrell High resolution two-dimensional electrophoresis of proteins. , 1975, The Journal of biological chemistry.